The standard recommended dose for most Candida infections is听fluconazole at 800 mg听as the loading dose, followed by fluconazole at a dose of 400 mg/d either intravenously or orally for at least 2 weeks of therapy after a demonstrated negative blood culture result or clinical signs of improvement.
The global Candidiasis Drug market is projected to reach US$ 1617.6 million in 2029, increasing from US$ 1163 million in 2022, with the CAGR of 4.8% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Candidiasis Drug market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Candidiasis Drug market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
Bayer
Perrigo
J & J
Pfizer
Bristol-Myers Squibb
Effik
Teva
Sanofi
Cisen Pharmaceutical
Kingyork Group
Segment by Type
Oral
External Use
Other
Segment by Application
Hospital
Retail Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Candidiasis Drug report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. 麻豆原创 Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: 麻豆原创 Conclusions
Chapter 13: Research Methodology and Data Source
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Candidiasis Drug 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Oral
1.2.3 External Use
1.2.4 Other
1.3 麻豆原创 by Application
1.3.1 Global Candidiasis Drug 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Candidiasis Drug 麻豆原创 Perspective (2018-2029)
2.2 Candidiasis Drug Growth Trends by Region
2.2.1 Global Candidiasis Drug 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Candidiasis Drug Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Candidiasis Drug Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Candidiasis Drug 麻豆原创 Dynamics
2.3.1 Candidiasis Drug Industry Trends
2.3.2 Candidiasis Drug 麻豆原创 Drivers
2.3.3 Candidiasis Drug 麻豆原创 Challenges
2.3.4 Candidiasis Drug 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Candidiasis Drug Players by Revenue
3.1.1 Global Top Candidiasis Drug Players by Revenue (2018-2023)
3.1.2 Global Candidiasis Drug Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Candidiasis Drug 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Candidiasis Drug Revenue
3.4 Global Candidiasis Drug 麻豆原创 Concentration Ratio
3.4.1 Global Candidiasis Drug 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Candidiasis Drug Revenue in 2022
3.5 Candidiasis Drug Key Players Head office and Area Served
3.6 Key Players Candidiasis Drug Product Solution and Service
3.7 Date of Enter into Candidiasis Drug 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Candidiasis Drug Breakdown Data by Type
4.1 Global Candidiasis Drug Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Candidiasis Drug Forecasted 麻豆原创 Size by Type (2024-2029)
5 Candidiasis Drug Breakdown Data by Application
5.1 Global Candidiasis Drug Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Candidiasis Drug Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Candidiasis Drug 麻豆原创 Size (2018-2029)
6.2 North America Candidiasis Drug 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Candidiasis Drug 麻豆原创 Size by Country (2018-2023)
6.4 North America Candidiasis Drug 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Candidiasis Drug 麻豆原创 Size (2018-2029)
7.2 Europe Candidiasis Drug 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Candidiasis Drug 麻豆原创 Size by Country (2018-2023)
7.4 Europe Candidiasis Drug 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Candidiasis Drug 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Candidiasis Drug 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Candidiasis Drug 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Candidiasis Drug 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Candidiasis Drug 麻豆原创 Size (2018-2029)
9.2 Latin America Candidiasis Drug 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Candidiasis Drug 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Candidiasis Drug 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Candidiasis Drug 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Candidiasis Drug 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Candidiasis Drug 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Candidiasis Drug 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bayer
11.1.1 Bayer Company Detail
11.1.2 Bayer Business Overview
11.1.3 Bayer Candidiasis Drug Introduction
11.1.4 Bayer Revenue in Candidiasis Drug Business (2018-2023)
11.1.5 Bayer Recent Development
11.2 Perrigo
11.2.1 Perrigo Company Detail
11.2.2 Perrigo Business Overview
11.2.3 Perrigo Candidiasis Drug Introduction
11.2.4 Perrigo Revenue in Candidiasis Drug Business (2018-2023)
11.2.5 Perrigo Recent Development
11.3 J & J
11.3.1 J & J Company Detail
11.3.2 J & J Business Overview
11.3.3 J & J Candidiasis Drug Introduction
11.3.4 J & J Revenue in Candidiasis Drug Business (2018-2023)
11.3.5 J & J Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Detail
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Candidiasis Drug Introduction
11.4.4 Pfizer Revenue in Candidiasis Drug Business (2018-2023)
11.4.5 Pfizer Recent Development
11.5 Bristol-Myers Squibb
11.5.1 Bristol-Myers Squibb Company Detail
11.5.2 Bristol-Myers Squibb Business Overview
11.5.3 Bristol-Myers Squibb Candidiasis Drug Introduction
11.5.4 Bristol-Myers Squibb Revenue in Candidiasis Drug Business (2018-2023)
11.5.5 Bristol-Myers Squibb Recent Development
11.6 Effik
11.6.1 Effik Company Detail
11.6.2 Effik Business Overview
11.6.3 Effik Candidiasis Drug Introduction
11.6.4 Effik Revenue in Candidiasis Drug Business (2018-2023)
11.6.5 Effik Recent Development
11.7 Teva
11.7.1 Teva Company Detail
11.7.2 Teva Business Overview
11.7.3 Teva Candidiasis Drug Introduction
11.7.4 Teva Revenue in Candidiasis Drug Business (2018-2023)
11.7.5 Teva Recent Development
11.8 Sanofi
11.8.1 Sanofi Company Detail
11.8.2 Sanofi Business Overview
11.8.3 Sanofi Candidiasis Drug Introduction
11.8.4 Sanofi Revenue in Candidiasis Drug Business (2018-2023)
11.8.5 Sanofi Recent Development
11.9 Cisen Pharmaceutical
11.9.1 Cisen Pharmaceutical Company Detail
11.9.2 Cisen Pharmaceutical Business Overview
11.9.3 Cisen Pharmaceutical Candidiasis Drug Introduction
11.9.4 Cisen Pharmaceutical Revenue in Candidiasis Drug Business (2018-2023)
11.9.5 Cisen Pharmaceutical Recent Development
11.10 Kingyork Group
11.10.1 Kingyork Group Company Detail
11.10.2 Kingyork Group Business Overview
11.10.3 Kingyork Group Candidiasis Drug Introduction
11.10.4 Kingyork Group Revenue in Candidiasis Drug Business (2018-2023)
11.10.5 Kingyork Group Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Bayer
Perrigo
J & J
Pfizer
Bristol-Myers Squibb
Effik
Teva
Sanofi
Cisen Pharmaceutical
Kingyork Group
听
听
*If Applicable.